Comparative Pharmacology
Head-to-head clinical analysis: CYLTEZO versus HUMIRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYLTEZO versus HUMIRA.
CYLTEZO vs HUMIRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
Tumor necrosis factor alpha (TNF-α) inhibitor; a recombinant human IgG1 monoclonal antibody that binds to soluble and membrane-bound TNF-α, preventing its interaction with p55 and p75 TNF receptors, thereby reducing inflammation and immune activation.
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
Adult: 40 mg subcutaneously every other week. For ulcerative colitis: initial dose 160 mg on day 1, then 80 mg on day 15, then 40 mg every other week starting day 29.
None Documented
None Documented
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in adults, supporting a subcutaneous dosing interval of every 2 weeks. Longer half-life in older patients.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Adalimumab is primarily eliminated via reticuloendothelial system degradation; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor